SLNO vs ACAD

ACADIA Pharmaceuticals Inc.

(ACAD) offers the better valuation at 9. 4x trailing P/E (48. 5x forward), making it the more compelling value choice. Analysts rate Soleno Therapeutics, Inc. (SLNO) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACADIA Pharmaceuticals Inc.

(ACAD) is the cheapest at 9. 4x versus Soleno Therapeutics, Inc. at 135. 7x. On forward P/E, Soleno Therapeutics, Inc. is actually cheaper at 13. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, ACADIA Pharmaceuticals Inc.

(ACAD) delivered a total return of +2. 5%, compared to -33. 4% for Soleno Therapeutics, Inc. (SLNO). Over 10 years, the gap is even starker: ACAD returned -22. 3% versus SLNO's -87. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Soleno Therapeutics, Inc.

(SLNO) is the lower-risk stock at 0. 92β versus ACADIA Pharmaceuticals Inc. 's 1. 26β — meaning ACAD is approximately 38% more volatile than SLNO relative to the S&P 500. On balance sheet safety, Soleno Therapeutics, Inc. (SLNO) carries a lower debt/equity ratio of 1% versus 4% for ACADIA Pharmaceuticals Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Soleno Therapeutics, Inc.

grew EPS 108. 9% year-over-year, compared to 68. 4% for ACADIA Pharmaceuticals Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus 11. 0% for Soleno Therapeutics, Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus 7. 9% for SLNO. At the gross margin level — before operating expenses — SLNO leads at 98. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Soleno Therapeutics, Inc.

(SLNO) trades at 13. 4x forward P/E versus 48. 5x for ACADIA Pharmaceuticals Inc. — 35. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ACAD: 61. 9% to $34. 78.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Soleno Therapeutics, Inc.

(SLNO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 92)). Both have compounded well over 10 years (SLNO: -87. 8%, ACAD: -22. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SLNO is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.